当前位置: X-MOL 学术Sleep Biol. Rhythm. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effects of stimulant treatment on sleep in attention deficit hyperactivity disorder (ADHD)
Sleep and Biological Rhythms ( IF 1.0 ) Pub Date : 2020-10-31 , DOI: 10.1007/s41105-020-00289-3
Miriam Sanabra , Tary Gómez-Hinojosa , Carlota Alcover , Oscar Sans , Jose A. Alda

The main objective of this study is to assess the prevalence of sleep disorders in treatment-naïve children and adolescents with ADHD compared with healthy controls matched for age and gender; and, at the same time, to determine whether stimulant medication (methylphenidate) affects sleep in the same group of children and adolescents with ADHD (naïve) after a 3-month treatment. A total of 120 children and adolescents (60 newly diagnosed with ADHD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV), and 60 gender- and age-matched controls) were evaluated through objective (actigraphy) and subjective (sleep diary) measures. Later, of those 60 newly diagnosed with ADHD, 30 started pharmacological treatment with methylphenidate with a mean daily dose of 0.58 mg/kg. No significant differences in both measures within the ADHD group after following the 3-month pharmacological treatment with methylphenidate were found. There were neither any significant differences in sleep parameters through objective measures between the medication-naïve ADHD group and the control group, while significant differences were found through sleep diary (registered by parents) in latency and efficiency ( p = < 0.05). These findings suggest that patients receiving a mean daily dose of 0.58 mg/kg of methylphenidate for 3 months did not experience sleep disturbances, based on objective (actigraphy) and subjective data. In addition, sleep problems in ADHD subjects may be overestimated by parents due to ADHD symptomatology.

中文翻译:

兴奋剂治疗对注意力缺陷多动障碍 (ADHD) 睡眠的影响

本研究的主要目的是评估与年龄和性别匹配的健康对照相比,未经治疗的 ADHD 儿童和青少年的睡眠障碍患病率;同时,确定兴奋剂药物(哌甲酯)是否会影响同一组多动症(初治)儿童和青少年在治疗 3 个月后的睡眠。共有 120 名儿童和青少年(60 名根据《精神疾病诊断和统计手册》第四版(DSM IV)新诊断为 ADHD,60 名性别和年龄匹配的对照)通过客观(动作记录)和主观(睡眠日记)措施。后来,在新诊断患有多动症的 60 人中,有 30 人开始使用哌醋甲酯进行药物治疗,平均每日剂量为 0.58 mg/kg。在使用哌醋甲酯进行 3 个月的药物治疗后,ADHD 组的两项指标均未发现显着差异。通过客观测量,未用药 ADHD 组和对照组之间的睡眠参数没有任何显着差异,而通过睡眠日记(由父母登记)发现潜伏期和效率存在显着差异(p = < 0.05)。这些发现表明,根据客观(活动记录)和主观数据,接受平均每日剂量为 0.58 mg/kg 哌甲酯 3 个月的患者没有出现睡眠障碍。此外,由于 ADHD 症状,父母可能高估了 ADHD 受试者的睡眠问题。通过客观测量,未用药 ADHD 组和对照组之间的睡眠参数没有任何显着差异,而通过睡眠日记(由父母登记)发现潜伏期和效率存在显着差异(p = < 0.05)。这些发现表明,根据客观(活动记录)和主观数据,接受平均每日剂量为 0.58 mg/kg 哌甲酯 3 个月的患者没有出现睡眠障碍。此外,由于 ADHD 的症状,父母可能会高估 ADHD 受试者的睡眠问题。通过客观测量,未用药 ADHD 组和对照组之间的睡眠参数没有任何显着差异,而通过睡眠日记(由父母登记)发现潜伏期和效率存在显着差异(p = < 0.05)。这些发现表明,根据客观(活动记录)和主观数据,接受平均每日剂量为 0.58 mg/kg 哌甲酯 3 个月的患者没有出现睡眠障碍。此外,由于 ADHD 的症状,父母可能会高估 ADHD 受试者的睡眠问题。而通过睡眠日记(由父母登记)发现潜伏期和效率存在显着差异(p = < 0.05)。这些发现表明,根据客观(活动记录)和主观数据,接受平均每日剂量为 0.58 mg/kg 哌甲酯 3 个月的患者没有出现睡眠障碍。此外,由于 ADHD 的症状,父母可能会高估 ADHD 受试者的睡眠问题。而通过睡眠日记(由父母登记)发现潜伏期和效率存在显着差异(p = < 0.05)。这些发现表明,根据客观(活动记录)和主观数据,接受平均每日剂量为 0.58 mg/kg 哌甲酯 3 个月的患者没有出现睡眠障碍。此外,由于 ADHD 的症状,父母可能会高估 ADHD 受试者的睡眠问题。
更新日期:2020-10-31
down
wechat
bug